Welcome to our dedicated page for Iteos Therapeutics news (Ticker: ITOS), a resource for investors and traders seeking the latest updates and insights on Iteos Therapeutics stock.
iTeos Therapeutics, Inc. (ITOS) is a clinical-stage biopharmaceutical company that has focused on immuno-oncology, developing therapies designed to counteract immunosuppressive pathways in the tumor microenvironment. Company communications describe programs targeting the TIGIT/CD226 axis, the adenosine pathway, ENT1, TREM2, and PTPN1/2, with candidates such as belrestotug, EOS-984, EOS-215, and inupadenant.
The news flow around iTeos has included clinical trial updates, collaboration decisions, strategic reviews, and corporate transactions. For example, the company has reported interim data from Phase 2 and Phase 3 studies in first-line non-small cell lung cancer and head and neck squamous cell carcinoma, including the GALAXIES Lung-201, GALAXIES Lung-301, GALAXIES H&N-202, and TIG-006 trials. In May 2025, iTeos and its partner GSK decided to terminate the belrestotug development program after interim analyses did not meet predefined criteria for progression-free survival and response rate improvements compared with monotherapy.
News items have also covered early-stage pipeline progress, such as Phase 1 development of EOS-984, IND-enabling and early clinical work for EOS-215, and preclinical data on a PTPN1/2 inhibitor. The company has presented data at major scientific and medical meetings, including the American Association for Cancer Research Annual Meeting and the ESMO Immuno-Oncology Congress, highlighting translational and preclinical findings on its candidates and pathway signatures.
In 2025, iTeos announced a strategic shift, stating its intention to wind down operations and focus on maximizing shareholder value through its cash position and potential asset sales. Subsequent news detailed an agreement for iTeos to be acquired by Concentra Biosciences through a tender offer and merger, followed by delisting from Nasdaq and deregistration of its common stock. This news page provides a record of these developments, allowing investors, researchers, and other readers to review the company’s clinical, scientific, and corporate milestones over time.
Summary not available.
Summary not available.
Summary not available.
iTeos Therapeutics (ITOS) reported its financial results for Q4 and FY 2022, highlighting a cash balance of $731.4 million, expected to support operations into 2026. The company is progressing with 10 clinical trials, notably the anti-TIGIT monoclonal antibody EOS-448 in collaboration with GSK, and the inupadenant program targeting the adenosine pathway. Net income for Q4 2022 was $20.5 million with EPS of $0.57, down from the previous year, reflecting increased R&D expenses of $25.4 million and G&A expenses of $11.1 million.
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a biopharmaceutical company focused on immuno-oncology, has announced that CEO Michel Detheux will present at the Cowen 43rd Annual Health Care Conference in Boston on March 7, 2023, at 9:10 a.m. ET. A live webcast of the presentation will be accessible on the company's Investors webpage, with a replay available for 30 days. iTeos is advancing innovative therapies aimed at enhancing immune responses against cancer, including EOS-448 and inupadenant. These programs target novel immuno-oncology pathways, reflecting the company’s commitment to improving clinical outcomes.
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a biopharmaceutical company focused on immuno-oncology therapies, has announced that its CEO, Michel Detheux, will present at the SVB Securities Global Biopharma Conference on February 14, 2023, at 10:00 a.m. EST. A live webcast of the presentation will be accessible on the company's website, with an archived replay available for 30 days post-event.
iTeos is developing innovative therapies, including EOS-448, an anti-TIGIT antibody in collaboration with GSK, and inupadenant, an adenosine A2A receptor antagonist entering proof-of-concept trials, targeting cancer immunosuppression.
iTeos Therapeutics has outlined significant advancements planned for 2023, focusing on its anti-TIGIT monoclonal antibody EOS-448 and adenosine A2A receptor antagonist inupadenant. The company is conducting eleven clinical trials across three programs, with EOS-984 expected to enter clinical studies in mid-2023. As of September 30, 2022, iTeos reported a robust cash position of $752 million, projected to support operations into 2026. CEO Michel Detheux emphasized the company's readiness to leverage their scientific expertise to move forward with promising immunotherapies.
iTeos Therapeutics (Nasdaq: ITOS), a biopharmaceutical firm focused on immuno-oncology, announced that CEO Michel Detheux will present at the 41st Annual J.P. Morgan Conference in San Francisco on January 10, 2023, at 8:15 a.m. PST. A live webcast of the event will be accessible on the company's website, with an archived replay available for 30 days post-presentation. iTeos is known for its innovative therapies aimed at enhancing the immune response against cancer, including its lead programs, EOS-448 and inupadenant.
iTeos Therapeutics (Nasdaq: ITOS) announces that Dr. Michel Detheux, CEO, will speak at the Piper Sandler 34th Annual Healthcare Conference in New York City on November 29, 2022, at 4:30 p.m. ET. A live webcast will be available on the company's website, with an archived replay accessible for 30 days post-event. iTeos specializes in immuno-oncology therapeutics, with programs like EOS-448, an anti-TIGIT antibody, and inupadenant, an adenosine A2A receptor antagonist, currently advancing in clinical trials.
iTeos Therapeutics (ITOS) reported its Q3 2022 results, highlighting the initiation of a Phase 2 trial for anti-TIGIT monoclonal antibody EOS-448 combined with GSK’s Jemperli in first-line metastatic non-small cell lung cancer (NSCLC).
The company holds a strong cash position of $752 million, projected to sustain operations into 2026. R&D expenses rose to $23.9 million, largely due to heightened clinical activities. Notably, net income declined to $1 million, or $0.03 per share, compared to $69.6 million in the same quarter last year.
FAQ
What is the current stock price of Iteos Therapeutics (ITOS)?
What is the market cap of Iteos Therapeutics (ITOS)?
